|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0015385,
umls-concept:C0025202,
umls-concept:C0027627,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0332293,
umls-concept:C0396670,
umls-concept:C0439064,
umls-concept:C0871261,
umls-concept:C1514474,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2587213,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-5-5
|
|
pubmed:abstractText |
In isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNFalpha) and interferon (IFN)-gamma, pioneered by Lienard and Lejenne in 1988, TNFalpha was empirically employed at a dosage (3-4 mg) ten times higher than the systemic maximum tolerable dose (MTD). We previously conducted a phase I/II study in 20 patients with in-transit melanoma metastases, using a combination of melphalan and TNFalpha at dosages ranging from 0.5 to 3.3 mg. The dose of 1 mg of TNFalpha was identified as optimal in terms of both efficacy and toxicity. The aim of the present study was to describe our experience with 113 stage IIIA/IIIAB melanoma patients treated with a TNFalpha-based ILP and identify prognostic factors for response, locoregional control and survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0258-851X
|
|
pubmed:author |
pubmed-author:AnzàMM,
pubmed-author:ArmentiAA,
pubmed-author:BottiCC,
pubmed-author:CavaliereFF,
pubmed-author:CorriasFF,
pubmed-author:Di AngeloPP,
pubmed-author:Di FilippoFF,
pubmed-author:Di FilippoSS,
pubmed-author:FerraresiVV,
pubmed-author:GarineiRR,
pubmed-author:GiacominiPP,
pubmed-author:GinebriAA,
pubmed-author:PasqualoniRR,
pubmed-author:PerriPP,
pubmed-author:RossiC RCR,
pubmed-author:SantinamiMM,
pubmed-author:SofraCC,
pubmed-author:SperdutiII
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
347-52
|
|
pubmed:meshHeading |
pubmed-meshheading:19414425-Adult,
pubmed-meshheading:19414425-Aged,
pubmed-meshheading:19414425-Aged, 80 and over,
pubmed-meshheading:19414425-Extremities,
pubmed-meshheading:19414425-Female,
pubmed-meshheading:19414425-Humans,
pubmed-meshheading:19414425-Male,
pubmed-meshheading:19414425-Maximum Tolerated Dose,
pubmed-meshheading:19414425-Melanoma,
pubmed-meshheading:19414425-Melphalan,
pubmed-meshheading:19414425-Middle Aged,
pubmed-meshheading:19414425-Neoplasm Metastasis,
pubmed-meshheading:19414425-Perfusion,
pubmed-meshheading:19414425-Prognosis,
pubmed-meshheading:19414425-Treatment Outcome,
pubmed-meshheading:19414425-Tumor Necrosis Factor-alpha
|
|
pubmed:articleTitle |
Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
|
|
pubmed:affiliation |
Department of Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy. difilippo@ifo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
